ProCE Banner Activity

CE

Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care

Video

Watch this on-demand webcast from a live AMCP satellite symposium to learn from clinical and managed care pharmacists about recent advances in ovarian cancer care, including strategies for equitable care delivery and pharmacist considerations for novel treatments.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: April 24, 2023

Expiration: April 23, 2024

Share

Faculty

Laura R. Bobolts

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

Colleen Bohnenkamp

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, Merck Sharp & Dohme LLC, and Novocure, Inc.

AstraZeneca

GSK

ImmunoGen, Inc.

Merck Sharp & Dohme, LLC

Novocure, Inc

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with ovarian cancer and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in the management of patients with ovarian cancer, including those with treatment-naive and relapsed ovarian cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging data on PARP inhibitors as single agents or in combination therapies for ovarian cancer

  • Determine individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed ovarian cancer that incorporate novel therapies and combination strategies

  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings

  • Identify strategies to promote optimal and equitable clinical integration of approved and emerging therapies for patients with ovarian cancer to reduce associated costs, minimize healthcare disparities, and improve outcomes for patients

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learning with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of ineligible company.

The faculty reported the following relevant financial relationships to products or devices they have with ineligible companies related to the content of this educational activity.

Primary Author

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Pompano Beach, Florida 

Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships to disclose.

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Colleen Bohnenkamp, PharmD, BCOP, BCPS, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-006-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.